381 related articles for article (PubMed ID: 29153631)
1. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users.
Schoedel KA; Stockis A; Sellers EM
Epilepsy Behav; 2018 Jan; 78():194-201. PubMed ID: 29153631
[TBL] [Abstract][Full Text] [Related]
2. Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.
Levy-Cooperman N; Schoedel KA; Chakraborty B; Blum D; Cheng H
Epilepsy Behav; 2016 Aug; 61():63-71. PubMed ID: 27315134
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.
Schoedel KA; Andreas JO; Doty P; Eckhardt K; Sellers EM
J Clin Psychopharmacol; 2017 Dec; 37(6):675-683. PubMed ID: 28926353
[TBL] [Abstract][Full Text] [Related]
4. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
[TBL] [Abstract][Full Text] [Related]
6. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Ufer M; Kelsh D; Schoedel KA; Dingemanse J
Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
[TBL] [Abstract][Full Text] [Related]
7. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological interactions between brivaracetam and ethanol in healthy males.
Kruithof AC; Watanabe S; Peeters PA; de Kam ML; Zuiker RG; Stevens J; van Gerven JM; Stockis A
J Psychopharmacol; 2017 Jul; 31(7):915-926. PubMed ID: 27649776
[TBL] [Abstract][Full Text] [Related]
10. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
11. Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users.
Schippers F; Pesic M; Saunders R; Borkett K; Searle S; Webster L; Stoehr T
J Clin Pharmacol; 2020 Sep; 60(9):1189-1197. PubMed ID: 32495449
[TBL] [Abstract][Full Text] [Related]
12. Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study.
Wilbraham D; Berg PH; Tsai M; Liffick E; Loo LS; Doty EG; Sellers E
J Clin Pharmacol; 2020 Apr; 60(4):495-504. PubMed ID: 31745991
[TBL] [Abstract][Full Text] [Related]
13. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.
Trinka E; Tsong W; Toupin S; Patten A; Wilson K; Isojarvi J; James D
Epilepsy Res; 2020 Oct; 166():106403. PubMed ID: 32673969
[TBL] [Abstract][Full Text] [Related]
16. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
Ge X; Henningfield JE; Siddhanti S; Jobes J; Lu L; Xie S; Ziola M; Kelsh D; Vince B; Di Fonzo CJ; Tagliaferri M; Zalevsky J; Doberstein SK; Hoch U; Eldon MA
Pain Med; 2020 Feb; 21(2):e114-e126. PubMed ID: 31553457
[TBL] [Abstract][Full Text] [Related]
17. Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.
Schoemaker R; Wade JR; Stockis A
Clin Pharmacokinet; 2018 Jul; 57(7):843-854. PubMed ID: 28884437
[TBL] [Abstract][Full Text] [Related]
18. Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.
Webster L; Henningfield J; Buchhalter AR; Siddhanti S; Lu L; Odinecs A; Di Fonzo CJ; Eldon MA
Pain Med; 2018 Feb; 19(2):307-318. PubMed ID: 28340145
[TBL] [Abstract][Full Text] [Related]
19. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
